Ardelyx, Inc. — Form 10-Q Summary
Reporting period: Quarter and nine months ended September 30, 2014. Ardelyx is a clinical-stage biopharmaceutical company with no commercial product sales. Its lead candidate, tenapanor, is licensed to AstraZeneca; Sanofi holds a research license and option relating to Ardelyx’s NaP2b inhibitors.
Financial performance and position
Amounts below are in millions of dollars except per-share data. Interim results are unaudited.
| Metric | Q3 2014 | Q3 2013 | Nine months 2014 | Nine months 2013 |
|---|---|---|---|---|
| Revenue | $7.60 | $6.59 | $25.28 | $20.44 |
| Operating expenses | $7.52 | $7.48 | $22.92 | $22.59 |
| Operating income (loss) | $0.08 | ($0.89) | $2.37 | ($2.15) |
| Net income (loss) | $0.07 | ($0.93) | $0.76 | ($2.30) |
| Operating cash flow | Not provided for quarter | Not provided for quarter | $17.19 | ($9.10) |
- Q3 revenue rose about 15% year over year: licensing revenue increased to $4.77 million from $1.99 million, while collaborative development revenue declined to $2.83 million from $4.60 million. Nine-month revenue increased about 24%.
- Q3 operating expenses were broadly flat, with lower R&D expense offset by higher general and administrative expense. For nine months, R&D expense was $18.51 million and G&A expense was $4.40 million.
- Q3 reported net income was $74,000. Nine-month net income attributable to common stockholders was zero after a $757,000 allocation for noncumulative preferred dividends; reported nine-month net income was $757,000. Per-share figures for 2014 are shown as dashes in the filing.
- At September 30, cash and cash equivalents were $112.04 million, total current assets $116.37 million, and current liabilities $19.40 million; working capital was approximately $97.0 million. The company reported no outstanding debt.
- Nine-month operating cash flow of $17.19 million benefited substantially from an $11.14 million increase in deferred revenue and other working-capital movements. Investing cash use was $0.82 million; financing cash inflow was $61.24 million, principally net IPO proceeds.
- Total deferred revenue was $51.44 million, including current and non-current portions. The company reported an accumulated deficit of $67.90 million.
Material changes and unusual items
- Ardelyx completed its IPO in June 2014, selling 4,928,900 shares at $14.00 per share and receiving $61.2 million in net proceeds. Preferred shares converted to common stock at the IPO, and the preferred-stock warrant liability was reclassified to equity.
- Licensing revenue increased mainly because the $15 million AstraZeneca development payment received in December 2013 and the $25 million payment received in May 2014 are being recognized over the estimated performance period, rather than fully when received. The $25 million payment followed dosing of the first patient in a Phase 2b hyperphosphatemia trial.
- During Q3, Ardelyx extended its estimated AstraZeneca performance period from December 2016 to December 2017, reflecting a later estimated completion of tenapanor Phase 2 trials. This affects the timing of deferred-revenue recognition.
- A noncash $1.59 million increase in the fair value of preferred-stock warrants reduced nine-month pretax income; the liability was extinguished upon the IPO-related warrant exercise and conversion.
- The company amended its Fremont lease in September, adding space and extending the term through September 2019. Future minimum lease payments total $4.39 million; the amendment provides for a tenant-improvement allowance of up to $600,000.
- A transition agreement provides for the Chief Scientific Officer’s departure on December 23, 2014 and accelerates vesting of restricted shares. Ardelyx recorded $203,000 of related stock compensation in Q3 and expected a further $633,000 charge in Q4.
Outlook, risks and other disclosures
- Management stated that existing capital resources were expected to fund projected operating requirements for at least the next 12 months, while cautioning that assumptions could change and additional capital may be needed. Ardelyx had no credit facility or other committed capital source beyond potential collaboration milestones.
- The company may elect to invest $20 million, $30 million or $40 million in the first tenapanor Phase 3 program to obtain a 1%, 2% or 3% increase, respectively, in royalties. The filing does not indicate that it had made this election.
- AstraZeneca was responsible for tenapanor development and commercialization costs under the collaboration. Ardelyx was eligible for up to $795 million in additional contingent payments at September 30, 2014: $197.5 million in development milestones and $597.5 million in launch, commercialization and sales milestones. These payments are contingent, not assured.
- Sanofi was responsible for research and preclinical costs under its NaP2b agreement and could exercise an option to obtain development and commercialization rights. Ardelyx was eligible for up to $196.8 million in potential milestones and tiered royalties if the program advances and a product is commercialized.
- Management expected unpartnered R&D expenses to increase as internal programs progress. Major risks include clinical-trial failure or delay, dependence on AstraZeneca and Sanofi decisions, regulatory and manufacturing uncertainty, competition, and the possibility of needing additional financing. The filing notes a prior tenapanor Phase 2a ESRD study that failed its primary endpoint and enrollment delays in an ongoing CKD Phase 2a study.
- The filing also cites positive Phase 2b IBS-C results announced by the company, while noting AstraZeneca may choose not to develop that indication. No specific trial effect-size or numerical efficacy details are provided in this filing text.
- Ardelyx reported effective disclosure controls as of September 30, 2014, no material changes to internal control over financial reporting during the quarter, and no material litigation.
Investor verification priorities
- Verify the timing and status of tenapanor trials, including the CKD enrollment delay, the ESRD program, and AstraZeneca’s decision-making on IBS-C and future development.
- Track AstraZeneca’s and Sanofi’s program progress, option decisions, and any milestone achievements; potential contingent payments should not be treated as committed liquidity.
- Assess the quality and sustainability of operating cash flow, particularly its reliance on deferred-revenue and working-capital movements, and compare cash burn with management’s 12-month liquidity assessment.
- Confirm whether Ardelyx elects to co-fund a tenapanor Phase 3 program and how the potential $20 million–$40 million commitment would affect runway.
- Monitor deferred-revenue recognition following the revised December 2017 performance-period estimate, as well as lease costs and the remaining stock-compensation charge related to the CSO transition.